The interaction of diltiazem with simvastatin

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 3, 2000, Pages 267-274

  Mousa, Omaima ^b   Brater, D Craig ^b   Sundblad, Kimberly J ^b   Hall, Stephen D ^a  

^a WISHARD MEMORIAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DILTIAZEM; HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG EFFECT; DRUG METABOLISM; DRUG MONITORING; ENZYME INHIBITION; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0042533918     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.104609     Document Type: Article

References (48)

1. 1. Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1995;50:334-63.
2. 2. Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM Jr, Mantell G. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. ClinTher 1992;14:708-17.
3. 3. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-54.
4. 4. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease. Lancet 1994;344:1383-9.
5. 5. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990;18: 138-45.
6. 6. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25:1191-9.
7. 7. Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990;18:476-83.
8. 8. Chaffman M, Brogden RN. Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs 1985;29:387-454.
9. 9. Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 1985;34:2549-53.
10. 10. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996;59:369-75.
11. 11. Thomas AR, Chan LN, Bauman JL, Olopade CO. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy 1998;18:381-5.
12. 12. Ahonen J, Olkkola KT, Salmenpera M, Hynynen M, Neuvonen PJ. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 1996;85:1246-52.
13. 13. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993;94:109-10.
14. 14. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R, Musso JL. Rhabdomyolysis with simvastatin use. Nephron 1991;57:365-6.
15. 15. Bertrand F, Fournier JP, Martinez P, Mahagne MH, Chichmanian RM, Ducoeur S, et al. [Acute rhabdomyolysis during treatment with simvastatin] [letter]. Therapie 1992;47:442.
16. 16. Alvarez JM, Rawdanowiz TJ, Goldstein J. Rhabdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin. J Thorac Cardiovasc Surg 1998; 116:654-5.
17. 17. Bizzaro N, Bagolin E, Milani L, Cereser C, Finco B. Massive rhabdomyolysis and simvastatin [letter]. Clin Chem 1992;38:1504.
18. 18. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin [letter]. Ann Intern Med 1991;114:342.
19. 19. Wicher-Muniak E, Zmudka K, Dabros W, Dudek D, Stachura J. Simvastatin-induced myopathy in a patient treated for hypercholesterolemia: morphological aspects. Pol J Pathol 1997;48:69-74.
20. 20. Meier C, Stey C, Brack T, Maggiorini M, Risti B, Krahenbuhl S. [Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity]. Schweiz Med Wochenschr 1995;125:1342-6.
21. 21. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 1997;90:546-7.
22. 22. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998;351: 1929-30.
23. 23. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997;277:296-7.
24. 24. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol 1994;33:199.
25. 25. Bannwarth B, Miremont G, Papapietro PM. Lupus-like syndrome associated with simvastatin. Arch Intern Med 1991;152:1093.
26. 26. Davidson MH, Stein EA, Dujovne CA et al. The efficacy and six week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997;79:38-42.
27. 27. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase [published erratum appears in Am J Cardiol 1994;74:639]. Am J Cardiol 1994;73:3D-11D.
28. 28. Galper JB. Increased incidence of myositis in patients treated with high-dose simvastatin [letter]. Am J Cardiol 1998;81:259.
29. 29. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369-77.
30. 30. Abernethy DR, Schwanz JB, Todd EL. Diltiazem and desacetyldiltiazem analysis in human plasma using high-performance liquid chromatography: improved sensitivity without derivatization. J Chromatogr 1985;342:216-20.
31. 31. Wu Y, Zhao J, Henion J, Korfmacher WA, Lapiguera AP, Lin CC. Microsample determination of lovastatin and its hydroxy acid metabolite in mouse and rat plasma by liquid chromatography/ionspray tandem mass spectrometry. J Mass Spectrom 1998;32:379-87.
32. 32. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83.
33. 33. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule for the calculation of the area under the plasma concentration-time curve. J Pharmacokinet Biopharm 1987; 6:539-46.
34. 34. Jacqz E, Hall SD, Branch RA, Wilkinson GR. Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a coregulated substrate, mephobarbital. Clin Pharmacol Ther 1986;39:646-53.
35. 35. Hoglund P, Nilsson LG. Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. Ther Drug Monit 1989;11:551-7.
36. 36. Cheng H, Schwanz MS, Vickers S, Gilbert JD, Amin RD, Depuy B, et al. Metabolic disposition of simvastatin in patients with T-tube drainage. Drug Metab Dispos 1994;22:139-42.
37. 37. Tobert JA, Vega JM, Dobrinska M, Gruer PJ. Calcium channel blocker-simvastatin interaction. Clin Pharmacol Ther 1999;65:582.
38. 38. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991;41:573-8.
39. 39. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82.
40. 40. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
41. 41. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
42. 42. Kivisto KT, Bookjans G, Fromm MF, Griese EU, Munzel P, Kroemer HK. Expression of CYP3A4, CYP3A5, and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996;42:387-9.
43. 43. Wilkinson GR, Shand DG. A physiological approach hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90.
44. 44. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of CYP3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999;290:1116-25.
45. 45. Rogers JD, Zhao J, Liu L, Amin RD, Gagliano KD, Porras AG, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999;66:358-66.
46. 46. Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agent Chemother 1993;37:265-9.
47. 47. Rowland Yeo K, Yeo WW, Wallis EJ, Ramsay LE. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br J Clin Pharmacol 1999;48:610-5.
48. 48. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156:2085-92.